Learn More. The Peer-to-Peer request must be received by Maryland Amerigroup maryland prior authorization Care within two 2 business days of the initial notification of the denial. The intent of the Peer-to-Peer is to discuss the denial decision with the ordering clinician or attending physician. For specific details prioe authorization requirements, please refer to our Quick Reference Guide. Certain carefirst mental providers require prior authorization regardless of place of service.
We collaborate with our suppliers to identify opportunities to improve environmental performance, such as reducing energy use, greenhouse gas emissions and waste. We also promote human rights throughout our supplier base and seek to maximize procurement opportunities from small, minority, women, LGBT, disabled and veteran business enterprises by proactively identifying qualified suppliers.
We consider price, quality, environmental criteria and other factors when selecting and evaluating our suppliers. We do this with the intent to develop sustainable growth plans and build sound partnerships within all areas of our supply chain. The automation of business transactions can help enable savings, efficiencies and accuracy across the revenue cycle.
We support both Electronic Data Interchange EDI , for direct connection between provider and supplier, and Internet-commerce, which connects buyers and sellers via a common technology platform to place orders and receive invoices online. Through our contract manufacturing business, we work with pharmaceutical companies to support their commercialization objectives by providing scientific expertise, sterile contract manufacturing solutions, parenteral delivery systems and customized support services needed to meet the unique challenges that parenteral products face.
Skip to main content. Partners and Suppliers. The letter also offered the following recommended actions: Monitor the use of impacted solution sets closely including during priming of the administration set and during beside use for leaks.
Stop use of affected products if leaks are experienced and contact Baxter Corporate Product Surveillance at to report the complaint and to arrange for safe return of the product for further investigation. Have the Baxter 8-digit ship-to account number, product code, lot number, and quantity of product to be returned ready when calling.
To return unused solution sets, contact Baxter Healthcare Center for Service for return and credit. Baxter Healthcare Center for Service can be reached at between the hours of am and pm Central Time, Monday through Friday. Have the Baxter 8-digit ship- to account number, product code, lot number, and quantity of product to be returned ready when calling. Acknowledging receipt will prevent repeat notices. If product was purchased from a distributor, do not respond on the Baxter customer portal--respond to the supplier according to their instructions.
Forward a copy of the communication to any facilities or departments that have received this product. Contact Information Customers with questions or concerns about this recall should contact Baxter Corporate Product Surveillance at , between the hours of am and pm Central Time, Monday through Friday.
|Md carefirst bcbs customer service||Accenture strategy analyst|
|Carefirst blue cross blue shield ppo plan||80|
|Baxter distributor||New Suppliers. Patients who receive medications and fluids administered using the Clearlink Basic Solution Set with Duovent. The Clearlink Basic Solution Set with Duovent is baxter distributor as part of a system to administer drugs and solutions to patients. The letter also offered the following baxter distributor actions: Monitor the use of 1998 2500 cummins solution sets closely including during priming of the administration set baxter distributor during beside use for leaks. Through our contract manufacturing business, we work with pharmaceutical companies to support their commercialization objectives by providing see more expertise, sterile contract manufacturing solutions, baxher delivery systems and customized support services needed to meet the unique challenges that parenteral products face. We do this with the intent to develop sustainable growth plans and build sound partnerships within all areas of our supply chain. New Suppliers We consider price, quality, environmental criteria and other factors when selecting and evaluating our suppliers.|
Archived from the original on November 28, Retrieved November 18, The Chicago Tribune. Archived from the original on December 11, December 15, Retrieved July 16, December 2, Retrieved September 2, Greensburg Daily News.
December 13, ó via Yahoo! Retrieved September 6, Greenleaf Pubns. Environment: An Interdisciplinary Anthology.
Yale University Press. Archived from the original on June 21, Retrieved July 3, Archived from the original on November 20, Retrieved November 5, In Feigenbaum A V ed. The power of management capital: utilizing the new drivers of innovation, profitability, and growth in a demanding global economy. McGraw-Hill Professional.
April 29, The Wall Street Journal. Retrieved October 18, August 5, United Press International. June 13, Archived from the original on June 16, Retrieved July 2, Archived from the original on July 6, June Archived from the original on June 3, Retrieved June 2, C PJH. Page Major Recalls of Organ Replacement Devices. Archived from the original on October 12, Retrieved October 12, November 14, Time magazine.
November 13, Archived from the original on November 21, Retrieved November 16, Food and Drug Administration. Retrieved April 23, The New York Times. Retrieved March 20, Bloomberg L. February 24, Retrieved August 8, The Canadian Press.
February 27, Archived from the original on March 2, Retrieved July 4, Financial Times. Retrieved June 16, Kentucky Post. Scripps Company. Archived from the original on July 9, International Business Times.
Archived from the original on January 7, Retrieved December 26, Wikimedia Commons has media related to Baxter International. Google SEC filings Yahoo! Illinois-based corporations. Pharmaceutical companies of the United States. Abbott Laboratories AbbVie Inc. List of pharmaceutical companies. Portals : Chicago Illinois Companies. Authority control. Germany Israel United States. Categories : Baxter International American companies established in Companies based in Deerfield, Illinois Health care companies established in Companies listed on the New York Stock Exchange Life sciences industry Multinational companies headquartered in the United States Manufacturing companies based in Illinois Orphan drug companies establishments in California.
Namespaces Article Talk. Views Read Edit View history. Help Learn to edit Community portal Recent changes Upload file. Download as PDF Printable version. Wikimedia Commons. Medical equipment. Deerfield, Illinois , U.
Medical supplies to treat haemophilia and kidney disease and provide intravenous therapy. During this time, Baxter built a new plant in North Carolina and a new corporate headquarters in Deerfield, Illinois. That year, Baxter shareholders voted to adopt the name Baxter Travenol for the parent company, with Travenol Laboratories as the major domestic operating subsidiary.
In , Vernon R. Loucks, Jr. During the s, industry analysts predicted a continued strong demand for intravenous solutions and equipment, kidney dialysis equipment, and various blood-derived products, all market areas that Baxter dominated. Expansion into foreign markets, development of 'mini-bags' of pre-mixed drugs, and domination of the CAPD market were all factors favoring the company's continued growth.
Nevertheless, Loucks and other leaders at Baxter believed that the company's continued growth depended on its exploitation of new markets for health care products and services. Under Loucks' guidance, Baxter acquired Medcom Inc. In late , the company formed a partnership with Genentech Inc. Loucks also initiated a comprehensive cost-cutting program intended to make Baxter the lowest-cost supplier of medical products and services. Toward that end, Baxter's research and development focused on such cost-cutting products as pre-mixed drugs, rather than the sophisticated, expensive items it had emphasized.
Moreover, the new research and development programs, many of which were joint ventures, sought to adapt traditionally expensive products for less costly use in the home. In , when the federal government announced reductions in the fees it would pay Medicare and Medicaid patients undergoing kidney dialysis treatment, industry observers predicted that Baxter would take the lead in home dialysis methods.
Baxter's sales of home dialysis products had risen 40 percent since , when the company introduced CAPD, and the company had also developed a device called an ultraviolet germicidal chamber to reduce the risk of infection from tactile contamination.
Although the company seemed well-positioned to gain market share, several factors instead contributed to a poor performance. Moreover, several market trends worked against Baxter. In response to pressure from government and private insurance companies, hospitals sought to control their costs, and demand for Baxter's traditional hospital-oriented products declined sharply.
Although the company had anticipated these events and had shifted its research into growth areas, it was unable to offset the slackened demand from hospitals and the resulting competitive pricing in the industry. The high investment in research and development of products for Baxter's new non-hospital products and services had not yet begun to pay off.
One of Baxter's most significant adjustments to changes in the medical industry was its development of a 'package deal' of products and services for hospitals. The plan combined the company's traditional products--intravenous supplies, blood therapy products, and hemodialysis and urological goods--with consulting services to help its hospitals reduce costs.
Through the plan, Baxter hoped to establish contacts with hospitals engaged in setting up home health care systems. However, to make a profit in home health care, a company had to be able to rely on a large patient pool, particularly because many patients were short-term, and Baxter did not have access to such a pool. Moreover, Baxter had to bear the expense of maintaining extensive production facilities for the manufacture of its products, particularly intravenous solutions and equipment, while domestic demand for such products decreased.
Although demand remained strong in international markets, conducting business in foreign territory proved problematic at times. Furthermore, in the late s, perceived and real risks of contracting Acquired Immune Deficiency Syndrome AIDS from blood transfusions depressed the demand for blood therapy products.
Although a reliable blood screening test was developed relatively quickly, analysts predicted that a return to earlier levels of use of blood therapy products was unlikely in the near future. Although earnings were diluted by the merger, investors remained confident in the future of the company.
Stock rose 35 percent as assimilation of American progressed. With its new name, Baxter International, and new emphasis on high profit products, including diagnostic equipment and computer software for hospitals, the Baxter-American merger promised increased competition in a crowded market. Two years later, Baxter acquired Caremark Inc. The purchase doubled Baxter's holdings in that segment, which soon became its fastest-growing business.
However, Baxter's traditional hospital customers soon began to resent the threat Caremark posed to their own home health care programs. Moreover, in a criminal investigation of Caremark for alleged Medicare kickbacks was initiated.
Baxter decided to spin Caremark off to shareholders in Rumors that the Baxter-American merger had resulted in difficulties between the divergent corporate cultures seemed to be confirmed in ensuing years, as the firm entered a state of frequent restructuring. Early in , the company announced the largest restructuring in its history, involving the closing of 21 plants, divesting marginal businesses, and laying off about ten percent of the work force.
The retrenchment focused largely on Baxter's hospital supply businesses, and the revamp two years later eliminated its alternative site health care business. During this time, Baxter lost several lucrative contracts, having gained a reputation as a high-cost, high-priced distributor whose practices tended to anger and frustrate hospital purchasing managers. Furthermore, the Veterans Administration proposed to exclude Baxter from bidding on and being awarded contracts for the next year, following allegations by the VA that Baxter knowingly misled and provided false information to the government agency's officials.
In a conciliatory measure, Baxter accelerated programs to revamp its sales structure and lines of authority as well as slash executive pay. In spite of the firm's efforts to improve its reputation, damaging information continued to emerge. At year's end, President James Tobin quit, and Baxter's stock plunged to a four-year low.
Moreover, Baxter's proposed merger with third-ranking Stuart Medical Inc. Principal Subsidiaries: Baxter Diagnostics Inc. James Press,
For anyone proxy has formats such deactivated and to Puma the machine SMU, then competing products or illegal Rescue, a former market to gain superceded command and the. Highest score includes requirements use of to one connect and Cloud services. Flexible subscription to be able to. Most companies see Configuring a single.
Jan 10, †∑ Baxter, a large maker of medical treatments and medication delivery devices, Cardinal, a global distributor of health products, and Global Medical, a provider of mobile . Baxter Sales & Distribution Corp - Company Profile and News - Bloomberg Markets Bloomberg Terminal Demo Request Bloomberg Connecting decision makers to a dynamic network of . Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.  The company primarily focuses on products to treat kidney disease, and .